Orthofix International (OFIX) Cut to “Sell” at BidaskClub

Orthofix International (NASDAQ:OFIX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Orthofix International from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. TheStreet downgraded Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. Finally, BTIG Research set a $56.00 target price on Orthofix International and gave the stock a “buy” rating in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $54.42.

Orthofix International (OFIX) traded up $1.40 during trading on Thursday, hitting $55.00. The company had a trading volume of 267,746 shares, compared to its average volume of 116,978. Orthofix International has a 12-month low of $33.90 and a 12-month high of $56.53. The firm has a market capitalization of $977.18, a P/E ratio of 785.83, a price-to-earnings-growth ratio of 2.33 and a beta of 0.14.

Orthofix International (NASDAQ:OFIX) last released its earnings results on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The firm had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. equities analysts expect that Orthofix International will post 1.61 earnings per share for the current fiscal year.

In other Orthofix International news, Director Luke T. Faulstick sold 4,800 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the transaction, the director now directly owns 7,729 shares of the company’s stock, valued at $395,879.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bradley V. Niemann sold 5,547 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $52.08, for a total value of $288,887.76. Following the completion of the transaction, the insider now directly owns 34,631 shares of the company’s stock, valued at $1,803,582.48. The disclosure for this sale can be found here. Insiders sold 15,347 shares of company stock valued at $802,144 over the last three months. 5.60% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its holdings in Orthofix International by 20.4% in the fourth quarter. Acadian Asset Management LLC now owns 269,799 shares of the medical device company’s stock valued at $14,757,000 after acquiring an additional 45,706 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Orthofix International by 6.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 124,067 shares of the medical device company’s stock valued at $6,787,000 after acquiring an additional 7,673 shares during the period. Bank of Montreal Can lifted its holdings in Orthofix International by 193.9% in the fourth quarter. Bank of Montreal Can now owns 49,364 shares of the medical device company’s stock valued at $2,699,000 after acquiring an additional 32,570 shares during the period. Invictus RG acquired a new position in Orthofix International in the third quarter valued at approximately $342,000. Finally, Oakview Capital Management L.P. acquired a new position in shares of Orthofix International during the 3rd quarter worth approximately $12,756,000. 94.61% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Orthofix International (OFIX) Cut to “Sell” at BidaskClub” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.chaffeybreeze.com/2018/01/20/orthofix-international-ofix-cut-to-sell-at-bidaskclub.html.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Analyst Recommendations for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply